Peritoneal dialysis therapy (PD) has a substantial need for biomarker as tools to identify patients that are at highest risk for PD-related complications and to guide personalised interventions that may improve clinical outcome in the individual patient. In this consensus paper, members of the European Training and Research in Peritoneal Dialysis Network (EuTRiPD) review the current status of biomarker research in PD and suggest a selection of biomarkers that might become relevant for the care of PD patients and which is directly accessible in PD effluents.
Background
Peritoneal dialysis (PD) is an effective, home-based form of renal replacement therapy that promotes patient autonomy. A significant proportion of patients who initiate PD suffer from PDrelated clinical complications that may limit duration of treatment, including peritonitis and peritoneal membrane damage. 1 PD patients are also at high risk of other serious and life threatening illnesses, most notably cardiovascular diseases. Current approaches to patient monitoring, however, are mostly limited to approximating delivered dose of dialysis and measurements of membrane transport status. Consequently, despite considerable improvements in patient management and overall technique survival, there is a substantial unmet medical need for biomarkers as tools to identify patients that are at the highest risk and to guide personalised interventions in order to improve clinical outcome of PD in the individual patient.
In the clinical context, a biomarker is a proxy of disease mechanisms, which gives relevant information for decision-making regarding the diagnosis and/or therapy of a patient. Another classical definition is: "A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological response to a therapeutic intervention". 2 This information may become directly obvious from the molecular processes that reflect disease status, such as increased levels of inflammatory mediators in biological fluids due to increased production and release from inflamed tissues or local leukocytes. However, biomarker levels may also reflect mere changes of distribution between compartments, such as leakage from intracellular into extracellular, or spill over from systemic into local compartments by altered clearance. 3 Accordingly, identification and interpretation of appropriate biomarkers is not trivial, and the clinical value of attractive biomarker candidates is difficult to predict and requires careful preclinical and clinical validation. 4 This consensus paper focuses on those biomarkers that are thought to be relevant for the care of PD patients, but are limited to the "local" peritoneal level, i.e., biomarkers that are directly high risk for PD-related complications might also allow a timely switch to alternate forms of renal replacement in non-responding patients. Importantly, combinations of these biomarkers may also be used as surrogate parameters for well-defined hard outcomes in the clinical development for novel PD fluids. Such biomarkers are particularly relevant tools as the "hard outcomes" require large studies with several hundred patients observed over several years and thus present major logistic and economic obstacles for dearly needed early clinical trials in PD. 1 Finally, biomarkers might also be implemented as a diagnostic tool. For example, a certain pattern of cytokines might reflect the nature of the causative pathogen in peritoneal infection and thus allow gaining quick and reliable diagnostic information relevant for therapeutic decisions (e.g., the guidance of antibiotic regime). 
Hypothesis-Driven Peritoneal Biomarker Research
The recent development of effluent biomarkers in PD has predominantly been hypothesisdriven and based on pathologies and pathomechanisms found to be relevant for the course of disease in PD. The biomarkers discussed in the following section are primarily related to chronic inflammation, peritoneal membrane remodeling and peritoneal infection.
Biomarker research in the context of Chronic Peritoneal Inflammation
Although not yet used in clinical routine, markers of chronic inflammation should be predictive of reduced survival in PD and HD patients, however, use of inflammatory cytokines and other related molecules as biomarkers must take into account of the complexity of their function and associations in this context. The most thoroughly studied marker of inflammation in PD patients is Interleukin-6 (IL-6), which is also a major target for therapy in other diseases. 6 Systemic levels of IL-6 and its soluble receptor are elevated in patients with end-stage renal disease (ESRD), and circulating IL-6 levels at initiation of PD therapy predict the mortality risk. 7 Multiple factors may contribute to circulating IL-6 levels, including persistent or episodic bouts of infection-inflammation, obesity, and metabolic alterations. Some of this excessive risk also appears to be genetically controlled, with polymorphisms in the IL-6 gene being associated with a high IL-6 producer status and reduced survival rates in patients undergoing PD. Impaired clearance of IL-6 in patients with severely diminished kidney function may also be contributing. Peritoneal mesothelial-to-mesenchymal transition (MMT) and inflammation establish a feedback loop in which the MMT process may induce inflammatory mediators, which again promote MMT. 31 Moreover, fibroblast play a role in this process. 32 As a result the peritoneal membrane undergoes a progressive remodeling with the accumulation of extracellular matrix and fibrosis. Peritoneal infections aggravate the peritoneal membrane remodeling process.
Patients who remain infection-free, however, also evidence PD induced inflammation and fibrosis, which may result in loss of peritoneal membrane function and ultimately cessation of PD. 33, 34 Assessment of the progressive morphological alterations would require repetitive peritoneal biopsies, which is, however, feasible in clinical routine only at time of catheter insertion and at time of subsequent abdominal surgery. 35 Alternatively, the ex vivo study of effluent-derived mesothelial cells might be useful to monitor peritoneal remodeling. 36 Effluent mesothelial cells show a progressive loss of epithelial phenotype and acquire fibroblastic characteristics through MMT. [37] [38] [39] MMT is a complex process during which mesothelial cells are transformed into fibroblast-like cells with the capacity of producing a wide spectrum of inflammation, fibrosis and angiogenesis mediators. 33 The ex vivo expression of molecules associated with MMT in effluent mesothelial cells is associated with peritoneal transport status. 40, 41 Moreover, levels of MMT-associated molecules in the PD effluent, including VEGF, 21 45 Experiments using inducible genetic fate mapping indicated type I collagenproducing submesothelial fibroblasts as specific progenitors of -SMA-positive myofibroblasts that accumulate progressively in animals exposed to sodium hypochlorite, hyperglycemic dialysis solutions, or TGF-1, suggesting an alternative mechanism of peritoneal fibrosis to MMT. 46 Moreover, fibroblasts expressing Thy-1 (CD90) appear to have an increased ability to acquire a myofibroblastic phenotype. 32 Thus, the proportion of Thy-1 + and Thy-1 − fibroblasts residing in the peritoneum may potentially identify individuals who are more prone to myofibroblast expansion following peritoneal injury.
Biomarker research in the context of Peritoneal Infection
Peritoneal infection remains one of the main culprits for technical failure and patient morbidity in PD. Whilst white cell counts (WCC) and the proportion of granulocytes in the peritoneal effluent are widely accepted as biomarkers for infection 47 less progress has been achieved in identifying biomarkers that discriminate between infection and non-infectious inflammation.
Culture-based diagnosis of infection is slow and error-prone, with 20-25% of cultures remaining negative despite distinct clinical and biochemical signs of bacterial infection. 48 Direct identification of pathogens using state-of-the-art technologies such as PCR or mass spectrometry with satisfactory sensitivity and specificity remains a challenge. 49 Culturenegative episodes of peritonitis may include cases of sterile inflammation that may not require antimicrobial therapy but are often masked by inappropriate sample processing or Moreover, levels of peritoneal effluent cytokines are lower in culture-negative episodes, with e.g., IL-1β and IL-10 showing potential for a distinction from infectious peritonitis.
When infection is present, biomarkers that are specifically associated with different types of pathogens, maybe useful to distinguish fungal, bacterial and viral infections and thus help inform the choice of treatment. In the absence of clear diagnostic parameters, prophylactic treatment of all peritonitis patients with antifungals has been recommended whenever a course of antibiotics is administered. 51 In the case of bacterial pathogens, early discrimination between Gram-positive and Gram-negative species would greatly reduce prescription of broad spectrum antibiotics, Gram stainings of patient samples are routinely performed but lack sensitivity. 52 The availability of pathogen-specific biomarker signatures, combined with the early identification of antimicrobial resistance patterns at the point of care, would represent a major breakthrough in the accurate diagnosis and targeted therapy of peritonitis. 53 For instance, biomarkers of particular relevance for the prediction of Gram-negative infections may include comparatively higher levels of the cytokines IL-1β, IL-10 and tumor necrosis factor (TNF)-α compared to Gram-positive infections, combined with larger numbers of infiltrating neutrophils and elevated frequencies of peritoneal γδ T cells.
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A biomarker predicting risk for infections might also help to guide clinical decisions to improve outcome in PD patients with compromised immunocompetence who are particularly susceptible for infectious complications. [54] [55] [56] [57] In critically ill patients depressed lipopolysaccharide (LPS)-stimulated release of TNF-α from whole blood has successfully been used to detect systemic immunosuppression and to monitor immunomodulatory therapies. [58] [59] [60] In PD, several studies have shown that ex-vivo stimulation of peritoneal macrophages isolated from PD effluents results in increased cytokine release compared to constitutive 53, 66 Biomarker research in the context of further pathomechanisms relevant to PD Cellular senescence is a complex biological program triggered by stimuli that can put the integrity of the genome at risk. 67 It is characterized by irreversible growth arrest, distorted cell morphology and altered cytokine secretion (including increased release of IL-6 and CXCL8). 68 Peritoneal mesothelial cells in mice exposed chronically to PD fluids exhibit a phenotype resembling that of senescent cells, 69 Likewise, the in vitro exposure of human peritoneal mesothelial cells to high concentrations of glucose results in accelerated development of the 70 partly through increased oxidative stress. 71 Consequently, the appearance of senescent mesothelial cells in the peritoneum may be indicative of peritoneal membrane deterioration. However, the clinical exploitation of this concept is hampered by the absence of a universal senescence marker 72 and difficulties in detecting senescent mesothelial cells in vivo. In this respect, it might be easier to detect senescence among mesothelial cells shed to the peritoneal effluent. 73 As oxidative stress is among the leading causes of premature senescence, the expression of oxidative stress biomarkers may be useful as surrogate indicators of peritoneal membrane deterioration. Oxidative stress is typically defined as a disturbance in the pro-oxidant / antioxidant balance in favor of the former. 74 Reliable markers of oxidative stress should consistently increase or decrease during periods of oxidative stress but not be impacted by other cellular processes. 75 However, the interpretation of changes in currently measured biomarkers of oxidative stress is challenging, as increased cellular antioxidant levels may either reflect an improved antioxidant status or a compensatory response to an oxidative insult. While several biomarkers of oxidative stress have been tested in PD patients such as advanced oxidized protein products (AOPP, see table 1) in peritoneal effluents [76] [77] [78] , the comprehensive assessment of a broad panel, especially in the context of cellular senescence, remains to be performed and validated in clinical outcome related research.
The combination of these pathomechanisms may result in abnormal cellular stress responses, potentially hampering peritoneal repair and propagating chronic inflammation. 79, 80 In experimental PD, cellular expression of the inducible 27 kDa and 70 kDa heat-shock proteins (Hsp27, Hsp72) has been shown to be dampened by PD fluid toxicity and inflammation. 80, 81 In effluent derived mesothelial cell cultures from PD patients, expression of Hsp27 and Hsp72 was demonstrated to be influenced by in vivo and ex vivo MMT processes. 82 Investigating the cellular stress responses at the proteome level (see also below) demonstrated an inadequate mesothelial Hsp72 expression that could be restored by therapeutic interventions. 83 These data suggest that the assessment of the adequacy of peritoneal cell stress responses might yield promising biomarkers to guide novel therapeutic interventions. To this end, alanyl- Importantly, the coverage of all molecules of a given type allows building statistical models not only relying on a single marker but on a collection of markers, best discriminating between different clinical outcomes, a so-called molecular signature. As single biomarkers can hardly reflect the biological complexity of underlying diseases, comorbidities, genetic background and context-dependent biological responses, molecular signatures are usually able to outperform individual surrogate markers and therefore may represent more relevant biomarkers.
Proteomics in the context of PD
In the field of PD only a limited number of 'omics studies has been performed, mostly trying to identify pathomechanisms in vitro or in animal models, or individual biomarkers in PD effluent.
Using in vitro models, proteomics identified a molecular signature of the stress response to 83, 86 . In animal models, a proteomic signature of extracellular matrix (ECM) proteins was employed to characterize the effect of specific gene deletion on MMT mechanisms. 87 None of these approaches have yet been applied to clinical samples. Whilst free-floating mRNA in PD effluent is difficult to use as a biomarker due to its limited stability, more stable species such as microRNAs should be potentially detectable in PD effluent and used as biomarkers. MicroRNAs are short RNAs that bind to specific proteincoding messenger RNA targets and repress synthesis of their respective proteins. There are ). 97, [106] [107] [108] Metabolomics in the context of PD PD effluent comprises of a significant amount of biological metabolites as well as small molecules originating from the original PD fluid and potential derivates, such as glucose adducts or break-down products of polymer osmotic agents. This fact renders metabolomics a particularly attractive technique for generating molecular signatures from PD effluent. Up to now a limited number of studies has been carried out, mainly focusing on proof-of-feasibility.
One study employed gas-chromatography coupled to MS or direct injection MS for generation of metabolomics profiles of PD effluent from patients who later developed EPS compared to matched controls. 109 One of the challenges in metabolomics analysis is the high redundancy of small molecule masses based only on their exact mass. Therefore in the second available study, a high resolution accurate mass (HR/AM) approach was combined with comparison of experimental and in-silico fragmentation of candidate molecules to increase the likelihood of unambiguous identification of metabolites increasing in PD effluent during a controlled 4 h PET dwell. 110 Defining phenotype associated molecular signatures in PD Currently only limited data from omics approaches using PD effluent as sample material is available. In the future, it would be particularly important to use biobanks generated from welldefined clinical cohorts in order to define molecular signatures reflecting the pro-inflammatory Figure 1 ).
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Smoldering Inflammation
Basal levels of cytokines in PD effluents are significantly associated with changes on peritoneal membrane transport characteristics, basal cytokine levels show no consistent differences between patients treated with different glucose-based PD fluids but significantly increased in PD patients treated with icodextrin containing regimens. 
Impaired

Host Defense
Ex-vivo stimulation of peritoneal macrophages isolated from PD effluents results in lower cytokine release in patients dialyzed with glucose based acidic single-chamber PD fluid than with pH neutral multi-chamber PD fluid. 55, [61] [62] [63] B * all published studies report discovery research data and are scored regarding their confirmation level: A: significant association in >3 independent studies with >100 PD patients; B: significant association in ≥3 independent studies; C: significant association in <3 independent studies 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 Biomarker research defined by a "targeted approach" starts hypothesis-driven from selected candidates, reflecting cellular mechanisms of interest, in the experimental setting and is then translated into the clinical context. Based on current evidence, the consortium selected surrogate biomarkers (given in bold) as endpoints to be assessed in a phase II clinical trial of a novel PD additive (EudraCT2013-000400-42/AT). The "open omics approach" starts with bio-material from well-defined clinical cohorts without any prior selection (non-hypothesis-driven). Clinical phenotypes to be assessed with molecular signatures (PAMS) as biomarkers were divided into pro-inflammatory and peritoneal membrane damage associated phenotypes. The pro-inflammatory phenotype was further divided into acute peritonitis and post-peritonitis triggered chronic inflammation. The membrane damage phenotype was further divided into mesothelial-tomesenchymal transdifferentiation (MMT) and changes in peritoneal membrane function determined by peritoneal equilibration testing. Ideally, the two approaches have to be applied iteratively and their results have to be integrated to foster successful biomarker research. The definition of biomarkers also reflects the currently available technologies in a given research field. Thus, the introduction of omics approaches and advanced statistical models to the field of PD is a quintessential prerequisite to describe and define future biomarkers in the open approach.
237x131mm (300 x 300 DPI) Figure 3 : Non-hypothesis-driven biomarker research following an open omics approach is particularly attractive using PD effluent (PDE) as source for sample material. The cellular fraction suspended in PDE can be analyzed using transcriptomics (focusing on mRNA) and proteomics techniques. For soluble substances in PDE (dissolved fraction), transcriptomics might be particularly attractive for micro RNAs (miRNA). Proteomics techniques can be applied but require prior removal of high abundance proteins and/or enrichment of low abundant biomarkers, and metabolomics techniques can be employed to quantify both endogenous metabolites and small molecules specific to PD fluid exposure. Identified molecules from all omics levels can be used for generation of pathogen associated molecular signatures (PAMS) using statistical modeling techniques. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
